IntelGenx Corp.
OTC Bulletin Board : IGXT

IntelGenx Corp.

April 30, 2007 11:58 ET

IntelGenx Technologies Corp. Signs licensing and Development Agreement

SAINT LAURENT, QUEBEC--(CCNMatthews - April 30, 2007) - IntelGenx Technologies Corporation (OTCBB:IGXT)("IntelGenx" or the "Company") today announced that the company signed a licensing and development agreement with a major US pharmaceutical company for the development and commercialization of a generic product.

As Dr. Horst Zerbe, CEO of the company, points out, the company has over the past year been successful in broadening its range of strategic alliances with partner companies in the US, Canada and Europe. The company currently has six partnered development programs with four development partners in place. The most recent partnership involves an oral tablet and uses Intelgenx' proprietary oral delivery technology. The product involves a widely prescribed drug with significant generic sales.

"The addition of this project to our portfolio represents an important milestone in our efforts to establish a robust pipeline of generic products involving our drug delivery technology and a strong partnership base with mid-to-large pharmaceutical companies around the world." said Dr. Horst Zerbe, Chief Executive Officer of IntelGenx Corp.

ABOUT INTELGENX CORP.

IntelGenx Corp. is an emerging drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company's research and development pipeline includes products for the treatment of nausea, pain management, hypertension, and smoking cessation.

FORWARD LOOKING STATEMENTS

This news release contains certain forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding potential product development and trial results, and the future plans and objectives of Intelgenx Corp. are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Intelgenx Corp's expectations are disclosed elsewhere in documents that are available to the public at www.sec.gov.

Contact Information